论文部分内容阅读
目的探讨分析微生态制剂预防婴幼儿抗生素相关性腹泻的临床疗效。方法回顾性分析2010年7月至2013年8月间在我院进行治疗的116例呼吸道感染患儿的临床记录资料。结果治疗后,观察组的腹泻发生率、腹泻次数、腹泻持续时间均明显少于对照组,差异均具有显著性(P<0.05);观察组的唾液sIgA含量和治疗前相比,差异无显著性(P>0.05),但对照组的唾液sIgA含量明显低于治疗前,差异具有显著性(P<0.05)。结论微生态制剂预防新生儿抗生素相关性腹泻的临床疗效显著,具有临床推广价值。
Objective To investigate the clinical efficacy of probiotics in the prevention of antibiotic-associated diarrhea in infants and young children. Methods The clinical records of 116 children with respiratory tract infection treated in our hospital from July 2010 to August 2013 were analyzed retrospectively. Results After treatment, the incidence of diarrhea, the frequency of diarrhea and the duration of diarrhea in the observation group were significantly less than those in the control group (P <0.05). There was no significant difference in sIgA content between the observation group and before treatment (P> 0.05). However, the salivary sIgA level in the control group was significantly lower than that before treatment (P <0.05). Conclusion The clinical efficacy of probiotics in preventing neonatal antibiotic-associated diarrhea is significant and has clinical value.